Huapont Life Sciences Co Ltd (002004) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Huapont Life Sciences Co Ltd (002004) has a cash flow conversion efficiency ratio of 0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥635.17 Million ≈ $92.95 Million USD) by net assets (CN¥16.10 Billion ≈ $2.36 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 002004 net asset quality index to measure how much of total assets are equity-financed.
Huapont Life Sciences Co Ltd - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Huapont Life Sciences Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 002004 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Huapont Life Sciences Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Huapont Life Sciences Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tekfen Holding AS
IS:TKFEN
|
0.085x |
|
Guobang Pharma Ltd
SHG:605507
|
0.036x |
|
The India Cements Limited
NSE:INDIACEM
|
-0.019x |
|
Gravita India Limited
NSE:GRAVITA
|
-0.021x |
|
Suzhou Victory Precision Manufacture Co Ltd
SHE:002426
|
0.002x |
|
Guangdong Tapai Group Co Ltd
SHE:002233
|
0.039x |
|
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.
SHG:605016
|
0.022x |
|
Suzhou Anjie Technology Co Ltd
SHE:002635
|
0.038x |
Annual Cash Flow Conversion Efficiency for Huapont Life Sciences Co Ltd (2002–2025)
The table below shows the annual cash flow conversion efficiency of Huapont Life Sciences Co Ltd from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see Huapont Life Sciences Co Ltd (002004) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥16.98 Billion ≈ $2.48 Billion |
CN¥2.10 Billion ≈ $306.72 Million |
0.123x | +17.53% |
| 2024-12-31 | CN¥15.47 Billion ≈ $2.26 Billion |
CN¥1.63 Billion ≈ $237.83 Million |
0.105x | +9.60% |
| 2023-12-31 | CN¥16.58 Billion ≈ $2.43 Billion |
CN¥1.59 Billion ≈ $232.59 Million |
0.096x | -34.12% |
| 2022-12-31 | CN¥16.55 Billion ≈ $2.42 Billion |
CN¥2.41 Billion ≈ $352.34 Million |
0.145x | +81.32% |
| 2021-12-31 | CN¥15.82 Billion ≈ $2.32 Billion |
CN¥1.27 Billion ≈ $185.79 Million |
0.080x | -52.20% |
| 2020-12-31 | CN¥14.14 Billion ≈ $2.07 Billion |
CN¥2.37 Billion ≈ $347.20 Million |
0.168x | +6.76% |
| 2019-12-31 | CN¥13.24 Billion ≈ $1.94 Billion |
CN¥2.08 Billion ≈ $304.68 Million |
0.157x | +5.02% |
| 2018-12-31 | CN¥12.75 Billion ≈ $1.87 Billion |
CN¥1.91 Billion ≈ $279.29 Million |
0.150x | +236.59% |
| 2017-12-31 | CN¥13.30 Billion ≈ $1.95 Billion |
CN¥591.40 Million ≈ $86.54 Million |
0.044x | -6.99% |
| 2016-12-31 | CN¥10.70 Billion ≈ $1.57 Billion |
CN¥511.90 Million ≈ $74.91 Million |
0.048x | +45.38% |
| 2015-12-31 | CN¥10.41 Billion ≈ $1.52 Billion |
CN¥342.45 Million ≈ $50.11 Million |
0.033x | -58.65% |
| 2014-12-31 | CN¥5.73 Billion ≈ $838.76 Million |
CN¥455.96 Million ≈ $66.72 Million |
0.080x | -8.68% |
| 2013-12-31 | CN¥4.01 Billion ≈ $587.13 Million |
CN¥349.51 Million ≈ $51.14 Million |
0.087x | -0.07% |
| 2012-12-31 | CN¥2.96 Billion ≈ $432.69 Million |
CN¥257.75 Million ≈ $37.72 Million |
0.087x | +66.69% |
| 2011-12-31 | CN¥2.59 Billion ≈ $378.40 Million |
CN¥135.23 Million ≈ $19.79 Million |
0.052x | -32.16% |
| 2010-12-31 | CN¥1.04 Billion ≈ $151.57 Million |
CN¥79.84 Million ≈ $11.68 Million |
0.077x | -44.01% |
| 2009-12-31 | CN¥897.32 Million ≈ $131.31 Million |
CN¥123.53 Million ≈ $18.08 Million |
0.138x | -1.49% |
| 2008-12-31 | CN¥814.07 Million ≈ $119.12 Million |
CN¥113.76 Million ≈ $16.65 Million |
0.140x | +28.94% |
| 2007-12-31 | CN¥730.86 Million ≈ $106.95 Million |
CN¥79.21 Million ≈ $11.59 Million |
0.108x | -14.27% |
| 2006-12-31 | CN¥522.90 Million ≈ $76.52 Million |
CN¥66.10 Million ≈ $9.67 Million |
0.126x | +27.50% |
| 2005-12-31 | CN¥440.68 Million ≈ $64.49 Million |
CN¥43.69 Million ≈ $6.39 Million |
0.099x | -43.60% |
| 2004-12-31 | CN¥401.64 Million ≈ $58.77 Million |
CN¥70.60 Million ≈ $10.33 Million |
0.176x | -54.80% |
| 2003-12-31 | CN¥145.74 Million ≈ $21.33 Million |
CN¥56.68 Million ≈ $8.29 Million |
0.389x | +7.74% |
| 2002-12-31 | CN¥102.18 Million ≈ $14.95 Million |
CN¥36.88 Million ≈ $5.40 Million |
0.361x | -- |
About Huapont Life Sciences Co Ltd
Huapont Life Sciences Co.,Ltd. engages in the medicine, medical care, agrochemicals, new materials, tourism, and other businesses in China and internationally. The company is involved in the production and sale of pharmaceutical preparations and raw materials. It also offers medicines for skin, tuberculosis, anti-infection, respiratory, anti-tumor, and cardiovascular, as well as health management… Read more